Succinylation-Associated LncRNA Signature as the Prognosis of Colon Cancer Identified by an Integrative Bioinformatics Analysis

Abstract

Though treatment techniques and strategies for colon cancer (CC) enhanced, the 5-year survival rate has not been significantly improved. Succinylation and long noncoding RNAs (lncRNAs) are uncertain for the prognostic value in the CC patients. We applied to analyze and obtain succinylation-related lncRNA by coexpression in CC. A novel succinylation-related lncRNA model was constructed by univariate and lasso regression analysis and established principal component analysis (PCA), functional enrichment annotation, tumor immune environment, drug sensitivity and nomogram to verify the model, respectively. Six succinylation-related lncRNA in CC were finally confirmed and distinguish the survival status in our model which was statistically significant differ in training set, testing set, and entire set. The prognosis value with this model associated with age, gender, M0 stage, N2 stage, T3+T4 stage and Stage III+IV. The high-risk group showed a higher mutation rate than the low-risk group. We constructed a model predict overall survival for 1-, 3-, and 5-year with AUCs of 0.694, 0.729, and 0.802. Cisplatin and Temozolomide compounds possess sensitivity in the high-risk group. Our study provided novel insights into the value of the succinylation related lncRNA signature as a predictor of prognosis, which possess high clinical application value in the future.

Construction and analysis of the CDKN2B-AS1 ceRNA network associated with KRAS-dependent tumorigenesis in colorectal and pancreatic cancer

“…Disturbances in lncRNAs, key regulators of gene expression, have been reported in the progression of many human cancers (11)(12)(13). Identifying the relationships between KRAS mutations and abnormal expression of some lncRNAs is expected to signi cantly improve our knowledge of the mechanisms of tumorigenesis controlled by mutKRAS (14).…”